Iowa Clinical Trials Report — June 2026

For Iowans considering participation in clinical research, June 2026 presents both urgent opportunities and significant new avenues for contribution. A critical window is closing for 40 clinical trials across the state that are slated to conclude within the next 90 days. This includes 3 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition before these opportunities vanish.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various gastrointestinal, hematologic, and cardiovascular conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Crohn's disease (2 trials)
• Carrier state (2 trials)
• Acute myeloid leukemia (1 trial)
• Adverse childhood experience (1 trial)
• AML (1 trial)
• AML with mutated NPM1 (1 trial)
• Atrial fibrillation (AF) (1 trial)
• Atrial arrhythmia (1 trial)
• Atrial tachycardia (1 trial)
• Cancer (1 trial)

Major Research Initiatives Launch Across Iowa

This month, Iowa welcomes 6 new clinical trials. While this is a decrease from the 12 trials that opened in May 2026, these new studies include several significant Phase 3 drug and biological trials from major pharmaceutical companies. These trials offer Iowans access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, migraine, and crucial vaccine development for infants.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 study titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants, evaluating the long-term efficacy, safety, and tolerability of aleniglipron for weight management.
• Another significant Phase 3 trial from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study will assess the long-term efficacy and safety of aleniglipron in 1,100 participants living with overweight or obesity and type 2 diabetes.
• Pfizer is leading an important Phase 3 vaccine trial, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to learn about the safety and effectiveness of a new pneumococcal vaccine in infants, helping to protect against pneumonia, meningitis, and otitis media.
• For those with type 2 diabetes, AstraZeneca is sponsoring NCT07662213, a Phase 3 study titled "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This trial plans for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes and increased cardiovascular risk.
• Individuals experiencing migraines may be interested in two new Phase 3 trials sponsored by Kallyope Inc. The first, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized study targeting 1,800 participants. The second, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," will evaluate the safety and tolerability of intermittent use of elismetrep in 1,000 participants.

New Research Opportunities Across Conditions and Interventions

The 6 new trials opening this month in Iowa cover a focused range of health conditions, primarily addressing metabolic health, migraine, and infectious disease prevention. The conditions addressed by these new studies include:

• Chronic weight management (2 trials)
• Obesity (2 trials)
• Overweight (2 trials)
• Type 2 diabetes mellitus (2 trials)
• Acute migraine (1 trial)
• Migraine (1 trial)
• Pneumococcal disease (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 5 of the new studies, with 1 new biological trial also opening. All 6 of these new studies are sponsored by industry, highlighting the significant investment from pharmaceutical companies in developing new treatments.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 6 new trials launched this month, 2 are actively seeking healthy volunteers. Statewide, a total of 80 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing healthcare for everyone.

Geographic Reach: Expanding Access Across Iowa

Iowa's clinical research landscape continues to be robust, with 764 clinical trials currently recruiting across 31 cities and 286 research sites statewide. This month, new research initiatives are spreading across several key areas. The cities with new trials opening include:

• West Des Moines (3 new trials)
• Iowa City (2 new trials)
• Ames (1 new trial)
• Ankeny (1 new trial)
• Des Moines (1 new trial)

This distribution ensures that residents in various regions of Iowa have access to cutting-edge research, from the larger metropolitan areas to other communities, making participation more accessible.

Inclusive Participation in Iowa Trials

Clinical trials in Iowa are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 1 includes children as participants, and 5 include older adults, ensuring that research benefits diverse age groups. All 6 of the new trials this month are sponsored by industry leaders such as Gasherbrum Bio, Inc., Kallyope Inc., AstraZeneca, and Pfizer, driving significant research efforts into new therapies and vaccines.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments and preventive measures for a broad spectrum of health challenges across Iowa.